Catalent Zydis® & OSDrC® OptiDoseTM Technologies

Jun 30, 2015
By PharmTech Editors

 

Catalent Zydis® & OSDrC® OptiDoseTM Technologies

Catalent's Zydis® orally disintegrating tablet (ODT) fast-dissolve formulation, is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water. This may enhance the performance and may also contribute towards better patient compliance.
With more than 20 products launched in 50 countries, Zydis is the world's best in class ODT technology. Whether to advance pharmacokinetics through pre-gastric absorption, improve patient compliance, or add marketing advantage to a valued brand, Catalent's customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product’s potential.

Catalent’s OSDrC® OptiDose™ is an innovative, flexible core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled release functionality and a range of unique dose forms, including fixed dose combination tablets.

With shown improvement in mass variability between layers, OptiDose offers tablet design, minimising cross-layer interaction and improving product stability.

In 2014, Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as gelatin-free encapsulation, chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.

Company name:  Catalent Pharma Solutions

Website: www.catalent.com

E-mail: info@catalent.com